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As occurs in any other vascularized organ, one of the essential functions of blood vessels in 
bone is to be a source of O2, nutrients, hormones and growth factors (1). However, additional 
roles for bone blood vessels are emerging. For example, osteoblast precursors have been 
recently identified within their wall (2,3), which suggests that blood vessels are a source of 
osteoprogenitors. Moreover, it has been shown that endothelial cells are specialized niches 
for hematopoietic stem cells (4,5). In light of these findings, identification of the molecular 
and cellular mechanisms controlling angiogenesis in bone is essential in order to reach a full 
understanding of how bone and bone marrow development and homeostasis are regulated.
In this issue of JBMR (6), Zhu and colleagues report that activating transcription factor-4 
(ATF4) promotes angiogenesis in bone. This effect is associated with an increased 
production of Vascular Endothelial Growth Factor - A (VEGF) by osteoblasts, and with 
stabilization of the hypoxia-inducible factor 1α (HIF-1α) in the same cells (6). It has been 
know for quite some time that ATF4 controls bone homeostasis by stimulating both 
osteoblastogenesis and osteoclastogenesis (7-10): Zhu and colleagues now add a new element 
to the picture by showing that mice lacking ATF4 have a reduced number of blood vessels 
in bone (6). The importance of their study is two-fold: first, it provides convincing evidence 
that ATF4 regulates bone angiogenesis in vivo and ex-vivo; second, it shows that ATF4 
contributes to stabilize HIF-1α protein in hypoxic-like conditions.
The vast majority of adult normal tissues functions at oxygen (O2) levels between 2% and 
9%, with ambient air at 21% O2 (11). Cartilage, bone marrow, kidney medulla and thymus, 
on the other hand, can exist at 1% O2 or lower (11) . When O2 tension goes below 2%, this 
condition is considered moderate hypoxia. When O2 tension goes below 0.5%, hypoxia is 
considered severe. Hypoxia-inducible factor-1 (HIF-1), a ubiquitously expressed 
transcription factor, is a major regulator of cellular adaptation to hypoxia (12-18). It is a 
heterodimeric DNA-binding complex that consists of two proteins, HIF-1α and HIF-1β (19). 
HIF-1α is activated when O2 levels drop below 5% (20-25). On the other hand, HIF-1β is 
non-oxygen responsive. HIF-1α does not directly sense variations of O2 tension (26); a class 
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of 2-oxoglutarate-dependent and Fe2+-dependent prolyl-4-hydroxylases (PHDs) are the O2 
sensors (20). PHDs hydroxylate two prolyl residues (P402 and P564) in the HIF-1α region 
referred to as the O2-dependent degradation domain (27). This modification occurs in 
normoxic conditions and mediates the binding of the von Hippel-Lindau tumor suppressor 
protein (pVHL), which is an E3 ubiquitin ligase, to HIF-1α HIF-1αis then marked with 
polyubiquitin chains and targeted for degradation by the proteosome. Under hypoxic 
conditions, the activity of the PHDs is impaired and proline hydroxylation cannot occur. As 
a result, HIF-1α protein accumulates and this initiates a multi-step pathway that includes 
nuclear translocation of HIF-1α, dimerization with its partner HIF-1β, recruitment of 
transcriptional co-activators, and binding to hypoxia-responsive elements within the 
promoters of hypoxia-responsive genes (28).
HIF-2α, another member of the family, has been recently identified and characterized (17). 
Similarly to HIF-1α, HIF-2α is degraded by the proteasome in normoxia, whereas it is 
stabilized in hypoxia (17,18). VEGF is one of the direct downstream targets of both HIF-1α 
and HIF-2α(17,29).
Despite its high degree of vascularization, a gradient of oxygenation is present in the bone 
marrow, and the endosteal surface of cortical bone is among the most hypoxic areas as 
revealed by staining with the marker of hypoxia pimonidazole (30-32). This gradient of 
oxygenation within the bone marrow is most likely created by the high degree of bone 
marrow cellularity, the high levels of O2 consumption by hematopoietic cells, and the slow 
flow in the bone marrow sinusoids (32,33).
Several laboratories are currently investigating how bone cells and bone blood vessels relate 
to each other. In particular, it has been recently shown that either osteoblastic stabilization 
HIFs or osteoblastic overexpression of VEGF, one of the most powerful proangiogenic 
growth factors, leads to a dramatic increase of trabecular bone and to a significant 
augmentation of the number and/or volume of bone marrow blood vessels (1,18,29,34-36). 
These findings have prompted researchers to conclude that an osteogenesis-angiogenesis 
coupling is likely to exist and to play a role in bone development and homeostasis (18). 
ATF4 has now been added to the list of transcription factors that control bone angiogenesis 
and, possibly, this osteogenesis-angiogenesis coupling (6). Notably, Zhu and colleagues 
show in their paper that ATF4 not only is sufficient to drive angiogenesis, but is also 
necessary to ensure a normal number of blood vessels in bone. Moreover, they propose, 
though they do not experimentally prove, that osteoblastic VEGF downstream of 
osteoblastic HIF-1α is the key mediator of this novel function of ATF4 (6). Increased release 
of VEGF from the matrix upon activation of bone resorption by osteoclasts could be an 
additional contributing factor (6).
Taken together, these are interesting and intriguing findings. However, since Zhu and 
colleagues have used for their study the global knockout of ATF4 rather than its conditional 
knockout in cells of the osteoblast lineage, at this stage we cannot conclude with absolute 
certainty that osteoblastic ATF4 is indeed the main responsible of the angiogenic phenotype 
observed in mutant mice lacking ATF4. Along these lines, the activation of osteoclasts and 
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the release of VEGF from the bone matrix occurring upon universal loss of ATF4 are 
probably both osteoblast–dependent and osteoblast-independent effects (6).
The notion of an osteogenesis-angiogenesis coupling, which would be essential not only in 
bone development and bone repair but also in bone homeostasis, is potentially very 
important. However, numerous issues still need to be addressed and resolved. Undoubtedly, 
all the studies presented and discussed to this end strongly suggest the existence of a 
correlation between these two events, osteogenesis and angiogenesis (1,3,18,29,34,35). 
Nonetheless, while it has been convincingly established that stabilization of HIFs in cells of 
the osteoblast lineage or overexpression of VEGF in the same cells causes a dramatic 
increase of bone mass in the trabecular compartment as well as an augmentation of bone 
vascularity(1,18,29,34-36), it has never been experimentally tested whether the increased 
number of blood vessels is an essential prerequisite for the high bone mass phenotype 
observed in these models. The same consideration applies to the global knockout of ATF4: 
loss of ATF4 impairs both bone mass and bone angiogenesis (6), but to this end we cannot 
unequivocally conclude that the decreased number of blood vessels is the main factor 
contributing to the low bone mass phenotype observed in ATF4 null bones. Supporting our 
concern, it has been recently shown that osteoblastic VEGF controls osteoblastogenesis 
mainly through an intracrine mechanism, rather than by regulating number of blood vessels 
in the bone marrow (37).
Moreover, it is well established that osteoblasts regulate bone marrow angiogenesis (18) and 
that VEGF is a very powerful proangiogenic factor (38), but the involvement of additional 
cytokines and/or growth factors produced by osteoblasts cannot be excluded.
In addition, the notion that also osteoclasts could be angiogenic cells by either producing 
angiogenic factors or by releasing them from the bone matrix has recently emerged (39).
Last, both ATF4 and HIFs are likely to control bone homeostasis with a variety of 
mechanisms that go beyond angiogenesis.
In this regard, HIF-1α is a crucial regulator of glucose metabolism. In aerobic conditions, 
glucose is converted to pyruvate in the cytoplasm. Pyruvate then enters the tricarboxylic 
acid (TCA) cycle and oxidative phosphorylation takes place in the mitochondria (40). Louis 
Pasteur was the first to record that O2 -deprived cells convert more glucose to lactate than 
cells in normoxic cultures. This is the so-called “Pasteur effect”. Induction of the Pasteur 
effect depends on HIF-1α which up regulates glucose transporters, glycolytic enzymes, and 
the enzyme lactic dehydrogenase (41-43). Moreover, HIF-1α inhibits mitochondrial oxidative 
phosphorylation, at least in part, by augmenting levels of pyruvate dehydrogenase kinase, an 
enzyme that phosphorylates and inhibits pyruvate dehydrogenase and thus conversion of 
pyruvate into acetyl CoA (44,45). By inhibiting the entry of pyruvate into the mitochondria, 
HIF-1α attenuates not only mitochondrial respiration, but also diminishes ROS production 
in hypoxic cells (46). Notably, it has been recently reported that both activation of non-
oxidative glycolysis and accumulation ROS significantly affect bone homeostasis (47-49), 
which implies that HIFs could indeed control bone mass at least in part by modulating 
glycolysis and oxidative phosphorylation in osteoblasts. With respect to ATF4, it has 
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already been unequivocally shown that ATF4 in osteoblasts activates both gene transcription 
and amino acid import, and both functions are crucially important for ATF4-dependent 
regulation of osteoblastogenesis (7-9).
Notably, ATF4 is a critical mediator of the endoplasmic reticulum stress response, 
particularly in hypoxic conditions (50). Hypoxia increases ATF4 levels in a HIF-independent 
manner (50), and, at least in part, through inhibition of PHD3 activity (51). These findings 
indicate that the PHD-oxygen sensing recruits both HIFs and ATF4. Zhu’s paper closes the 
loop between hypoxia, ATF4 and HIF-1α by showing that in cells of the osteoblast lineage, 
ATF4 is essential for proper stabilization of HIF-1α in hypoxia (6). The details of this 
interaction are not yet clear, though they may again involve the oxygen sensing machinery. 
In any event, the finding that HIF-1α and ATF4 appear to converge on common O2/nutrient 
sensing pathways in higher animals is consistent with the emergence of these two 
transcriptional pathways at a similar time in metazoan evolution (52,53) Interestingly, also 
RUNX2, another regulator of VEGF expression (54), has been reported to interact with 
HIF-1α and control its stability (55).
All in all, an interesting feedback mechanism has been established in which hypoxia 
increases ATF4 stability in a HIF-independent fashion, and this leads to further stabilization 
of HIF-1α with modalities that need to be further elucidated. At this stage, it is unknown 
whether this novel loop occurs only in osteoblastic cells, or whether indeed is a more 
general mechanism of HIF-1α regulation also present in other cell types. Moreover, it is 
unknown whether stabilization of HIF-2α in hypoxia does require interaction with ATF4.
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